Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Unknown 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Conditions

Breast Neoplasms 91Carcinoma, Non-Small-Cell Lung 53Lung Neoplasms 22Hodgkin Disease 15Recurrence 11Lymphoma 10Neoplasm Metastasis 9Prostatic Neoplasms 7Triple Negative Breast Neoplasms 6Neoplasms 6Sarcoma 4Rhabdomyosarcoma 4Lymphoma, Non-Hodgkin 4Lymphoma, Large B-Cell, Diffuse 4Adenocarcinoma of Lung 4Multiple Myeloma 3Mesothelioma, Malignant 3Mesothelioma 3Breast Neoplasms, Male 3Uterine Cervical Neoplasms 2Ovarian Neoplasms 2Neuroblastoma 2Melanoma 2Lymphoma, Large-Cell, Anaplastic 2HER2-negative Breast Cancer 2Fallopian Tube Neoplasms 2Esophageal Squamous Cell Carcinoma 2Colonic Neoplasms 2Brain Neoplasms 2Advanced Breast Cancer 2

Interventions

Vinorelbine 1Capecitabine 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 2 × Pathologic Residual Cancer Cells × Vinorelbine × Clear all
NCT03703427 2018-10-12

Capecitabine Versus Vinorelbine in High Risk Breast Cancer With Pathologic Residual Tumors After Preoperative Chemotherapy

Shandong Cancer Hospital and Institute

Phase 2 Unknown
200 enrolled

Pathologic Residual Cancer Cells

Data powered by HemOnc (CC BY 4.0) Colophon âš¡